Perimenopause hormone therapy: are 'better options' real?

What did @dromarakhter actually say?

Dr. Akhter argued that primary care physicians and gynecologists are too quick to prescribe SSRIs and oral contraceptives to perimenopausal women instead of bioidentical hormones like micronized progesterone and estradiol. The core claim: "there are better options out there" and women "don't need to be resigned to an SSRI or to birth control."

The video describes a patient in her late 40s with fatigue, poor mood, and weight gain. Her PCP offered an SSRI; her gynecologist offered birth control. Dr. Akhter frames this as a systemic failure to use what she calls "true hormone replacement therapy." The framing is pointed, the frustration is real, and a lot of patients watching will recognize themselves in this story. That emotional resonance doesn't make every claim accurate, though.

Does the science back this up?

Partly. The evidence for hormone therapy in perimenopause is genuinely stronger than clinical practice currently reflects, but the picture is messier than this video lets on.

The 2022 Menopause Society (NAMS) position statement supports low-dose hormone therapy as an effective option for vasomotor symptoms, mood disturbance, and sleep disruption in perimenopausal women under 60 without contraindications. A 2023 Lancet review (Davis et al.) confirmed estradiol-based therapy outperforms placebo for mood symptoms in perimenopause specifically, not just postmenopause. Micronized progesterone (Prometrium, or its generics) has a better safety profile than synthetic progestins, particularly for breast tissue and cardiovascular outcomes, per Fournier et al. (2008, Breast Cancer Research and Treatment).

However, SSRIs are not useless here. Escitalopram and venlafaxine have Level I evidence for vasomotor symptom reduction in women who cannot or choose not to use hormones (Loprinzi et al., multiple trials). Calling them categorically wrong overstates the case.

What did they get wrong (or right)?

Credit where it is due: the underuse of hormone therapy in perimenopause is a real and documented problem. A 2022 survey in Menopause (Crandall et al.) found that fewer than 30% of eligible perimenopausal women were ever offered hormone therapy by their provider. The reflexive reach for SSRIs in women presenting with mood symptoms, without first evaluating hormonal status, is a legitimate clinical concern. Dr. Akhter is on solid ground criticizing that pattern.

Where this video stumbles is in the framing of SSRIs and birth control as simply wrong. Low-dose combined oral contraceptives are actually guideline-supported for perimenopausal symptom management and contraception, particularly in nonsmoking women under 50 (ACOG Practice Bulletin 2022). They are not the same as HRT, but they are not the wrong call in every case. Presenting this as a binary, where hormones are right and everything else is a failure, shortcuts a conversation that should be individualized.

The term "bioidentical" also deserves scrutiny. When referring to FDA-approved micronized progesterone and estradiol patches, the science is solid. When the word gets used to implicitly endorse compounded hormone preparations, the evidence base is far weaker. This video does not explicitly recommend compounded hormones, but the language of "true hormone replacement" and "bioidentical" can push patients in that direction.

What should you actually know?

Perimenopause is undermanaged, and Dr. Akhter is right that women deserve more than a default SSRI prescription handed over without a hormonal workup. FDA-approved estradiol patches and micronized progesterone are well-studied, have a favorable risk profile in healthy women under 60, and are first-line options per NAMS, the British Menopause Society, and the Endocrine Society.

But "better options" does not mean one-size-fits-all. SSRIs remain appropriate for women with contraindications to estrogen, history of hormone-sensitive cancers, or personal preference. Oral contraceptives have a legitimate role in perimenopausal symptom management when selected appropriately. The failure is not that these drugs exist; it is that providers are skipping the conversation about what each patient actually needs.

• If you are in perimenopause and feel dismissed, you are not imagining it. Provider education gaps are real.
• Ask specifically about estradiol and micronized progesterone. Those are FDA-approved drugs with decades of safety data.
• Be cautious about compounded "bioidentical" hormone preparations. They are not equivalent to FDA-approved versions and lack the same safety and efficacy data.
• SSRIs are not inherently wrong for perimenopausal mood symptoms, but they should not be the first and only conversation.